Palisade Bio, Inc. - Common Stock (PALI)

Let's have a look at what is happening on the US markets on Friday. Below you can find the stocks with an unusual volume in today's session.

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Palisade Bio progresses its Phase 1 study for PALI-2108, showing safety and targeted bioactivation, with topline data anticipated in early 2025.

PALI stock results show that Palisade Bio missed analyst estimates for earnings per share the second quarter of 2024.

PALI stock results show that Palisade Bio beat analyst estimates for earnings per share the first quarter of 2024.

Palisade Bio entered into a collaboration with Strand Life Sciences is aimed at advancing precision medicine for ulcerative colitis (UC) therapy and provides the company access to advanced bioinformatics tools vital for understanding complex disease pathways and predicting responses to PDE4 inhibitors.

It's time to start ofd the trading week with a look at the biggest pre-market stock movers traders need to watch on Monday morning!

U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling around 0.3% on Tuesday. The Dow traded up 0.02% to 37,741.96 while the NASDAQ fell 0.20% to 15,853.39. The S&P 500 also fell, dropping, 0.28% to 5,047.76.

Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.